Allianz Asset Management GmbH Has $25.73 Million Stock Holdings in Encompass Health Co. (NYSE:EHC)

Allianz Asset Management GmbH grew its position in shares of Encompass Health Co. (NYSE:EHC) by 40.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 278,593 shares of the company’s stock after acquiring an additional 80,504 shares during the quarter. Allianz Asset Management GmbH’s holdings in Encompass Health were worth $25,728,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in EHC. MassMutual Private Wealth & Trust FSB boosted its holdings in Encompass Health by 87.8% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 293 shares of the company’s stock worth $27,000 after purchasing an additional 137 shares during the last quarter. Avior Wealth Management LLC bought a new stake in Encompass Health during the 3rd quarter worth about $40,000. Tompkins Financial Corp acquired a new position in shares of Encompass Health during the 4th quarter worth about $46,000. V Square Quantitative Management LLC grew its holdings in shares of Encompass Health by 43.8% in the 4th quarter. V Square Quantitative Management LLC now owns 581 shares of the company’s stock valued at $54,000 after acquiring an additional 177 shares in the last quarter. Finally, Morse Asset Management Inc acquired a new stake in shares of Encompass Health in the third quarter valued at about $68,000. 97.25% of the stock is owned by institutional investors.

Insider Activity at Encompass Health

In other news, CAO Andrew L. Price sold 5,042 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $98.29, for a total value of $495,578.18. Following the completion of the sale, the chief accounting officer now owns 69,164 shares of the company’s stock, valued at approximately $6,798,129.56. The trade was a 6.79 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 2.10% of the stock is currently owned by corporate insiders.

Encompass Health Price Performance

NYSE:EHC opened at $98.86 on Tuesday. The firm’s fifty day moving average price is $96.01 and its two-hundred day moving average price is $96.05. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.05 and a quick ratio of 1.04. The company has a market cap of $9.96 billion, a P/E ratio of 22.17, a P/E/G ratio of 2.31 and a beta of 0.90. Encompass Health Co. has a one year low of $73.68 and a one year high of $104.55.

Encompass Health (NYSE:EHC) last released its quarterly earnings results on Thursday, February 6th. The company reported $1.17 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.12. Encompass Health had a net margin of 8.48% and a return on equity of 17.56%. Equities analysts expect that Encompass Health Co. will post 4.8 earnings per share for the current year.

Encompass Health Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, April 17th. Investors of record on Tuesday, April 1st will be issued a dividend of $0.17 per share. The ex-dividend date of this dividend is Tuesday, April 1st. This represents a $0.68 annualized dividend and a yield of 0.69%. Encompass Health’s payout ratio is currently 15.25%.

Analyst Ratings Changes

Several brokerages recently commented on EHC. StockNews.com raised Encompass Health from a “hold” rating to a “buy” rating in a research report on Saturday, February 15th. Royal Bank of Canada reissued an “outperform” rating and issued a $110.00 price objective on shares of Encompass Health in a report on Tuesday, February 11th. Truist Financial reissued a “buy” rating and issued a $116.00 target price (up from $108.00) on shares of Encompass Health in a research note on Wednesday, October 30th. William Blair reaffirmed an “outperform” rating on shares of Encompass Health in a research report on Friday, February 7th. Finally, Barclays lifted their price objective on shares of Encompass Health from $116.00 to $118.00 and gave the company an “overweight” rating in a research report on Friday, February 7th. Ten research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $107.67.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.